Osinib 80mg (Osimertinib)

Osinib is a drug manufactured by Drugs International LTD (Bangladesh) with the main ingredient Osimertinib effective in adjuvant treatment after complete tumor resection in adult patients with non-small cell lung cancer.

Ingredients of Osinib

• Osimertinib 80mg.

Dosage forms

• Film-coated tablets.

Uses and indications of Osinib

Osinib as monotherapy is indicated for:

• Adjuvant treatment after complete tumor resection in adult patients with stage IB-IIIA non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) exons 19 or exon 21 substitution mutation (L858R).
• First-line treatment of adult patients with locally advanced or metastatic NSCLC with activating EGFR mutations.
• Treatment of adult patients with locally advanced or metastatic EGFR T790M mutation-positive NSCLC.

How to use - Dosage of Osinib

• How to use:
  • Medicines for oral use.
• • Dosage:
    • The recommended dose is 80mg osimertinib once a day (1 tablet).
    • Patients in the adjuvant setting should be treated until disease relapse or unacceptable toxicity occurs. Treatment durations of more than 3 years were not studied.
    • Patients with locally advanced or metastatic lung cancer should be treated until disease progression or unacceptable toxicity.

  Contraindications of Osinib

  • Contraindicated in patients with hypersensitivity to any ingredient in the drug, including pharmaceutical ingredients and excipients.

  Notes when using Osinib

  • Osimertinib may cause serious side effects on your heart, lungs, or vision.
  • Call your doctor at once if you have a fast or pounding heartbeat, swelling in your lower legs, cough, fever, trouble breathing, vision changes, eye pain, increased sensitivity to light, or if you feel light-headed head.
  • Tell your doctor if you have ever had:
    • respiratory disorders;
    • Electrolyte imbalance (such as high or low levels of calcium, potassium, or magnesium in the blood);
    • Eye problems;
    • Long QT syndrome (in you or a family member).
  • Osimertinib may harm an unborn baby if the mother or father is using osimertinib.
  • When using the drug, regular blood tests are required. Heart function may need to be tested with an electrocardiogram or ECG (sometimes called an EKG).
  • Osimertinib is usually taken until the body no longer responds to the drug.

  Use for pregnant or breastfeeding women

  • Women who are pregnant or breastfeeding should consult their doctor.

  For use by drivers and machine operators

  • Drivers and machine operators should consult a doctor.

  Osinib side effects

  • The most common adverse reactions (>20%) in all patients treated with Osimertinib were diarrhea (42%), rash (41%), dry skin (31%), and nail toxicity (25%). %).
  • The most common adverse reactions leading to dose reduction or interruption were: ECG QTc prolongation (2.2%) and neutropenia (1.9%).
  • Serious adverse reactions reported in 2% or more of patients were pneumonitis and pulmonary embolism.
  • Inform your doctor of any unwanted effects you encounter when using the drug.

  Interact

  • Strong CYP3A4 sensor, thus affecting drugs metabolized through CYP3A4.
  • If concurrent use is unavoidable, increase the Osimertinib dose to 160 mg daily when coadministered with a strong CYP3A inducer. Continue Osimertinib 80mg 3 weeks after discontinuation of the strong CYP3A4 inducer.

  Missed dose and treatment

  • Take the dose as soon as you remember. Do not take a second dose to make up for a dose you may have missed. Just continue with the next dose.

  Overdose and treatment

  • If an overdose occurs, notify your doctor immediately, or if you see unusual symptoms, go to the hospital for timely treatment.

  Preserve

  • Dry, airy place, temperature below 30 degrees Celsius, avoid direct sunlight.
  • Keep out of reach of children.

  Packing

  • Box of 30 tablets.